Medically reviewed by Drugs.com. Last updated on Jun 28, 2020.
(GAL ka NEZ ue mab)
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Solution Auto-injector, Subcutaneous [preservative free]:
Emgality: galcanezumab-gnlm 120 mg/mL (1 mL) [contains polysorbate 80]
Solution Prefilled Syringe, Subcutaneous [preservative free]:
Emgality: galcanezumab-gnlm 120 mg/mL (1 mL) [latex free; contains polysorbate 80]
Emgality (300 MG Dose): Galcanezumab-gnlm 100 mg/mL (1 mL) [latex free; contains polysorbate 80]
Brand Names: U.S.
- Emgality (300 MG Dose)
- Antimigraine Agent
- Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonist
- Monoclonal Antibody, CGRP Antagonist
Galcanezumab is a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor.
Vd: 7.3 L
Expected to be degraded into small peptides and amino acids via catabolic pathways similar to that which is seen with endogenous IgG.
Time to Peak
Use: Labeled Indications
Cluster headache (prevention): Preventative treatment of cluster headache during cluster episodes in adults.
Migraine prophylaxis: Preventive treatment of migraine in adults.
Serious hypersensitivity to galcanezumab or any component of the formulation.
Cluster headache (prevention): SubQ: 300 mg at the onset of the cluster period and then once monthly until the end of the cluster period.
Migraine prophylaxis: SubQ: Initial: 240 mg as a single loading dose, followed by 120 mg once monthly.
Missed dose: Administer missed doses as soon as possible and schedule monthly from the date of the last injection.
Refer to adult dosing.
SubQ: For subcutaneous use only; intended for self-administration. Keep out of direct sunlight. Prior to administration, allow to come to room temperature for 30 minutes. Do not warm using a heat source (eg, microwave or hot water). Do not shake. Administer in abdomen (avoiding 2 inches around the navel), thigh, upper arm, or buttocks avoiding areas of skin that are tender, bruised, red or hard. Deliver entire contents of single-use prefilled pen or syringe. Administer the 240 mg loading dose as 2 injections of 120 mg, one after another, and the 300 mg dose as 3 injections of 100 mg, one after another.
Store at 2°C to 8°C (36°F to 46°F) in the original carton. Protect from light until time of use. If necessary, may be stored at room temperature (up to 30°C [86°F]) in the original carton for up to 7 days; do not return back to the refrigerator. Discard if storage conditions are exceeded. Do not freeze or shake.
There are no known significant interactions.
Immunologic: Antibody development (5% to 13%; neutralizing: ≥50%)
Local: Injection site reaction (18%)
Frequency not defined: Hypersensitivity: Hypersensitivity reaction
Postmarketing: Anaphylaxis, angioedema, skin rash
Concerns related to adverse effects:
• Hypersensitivity: Hypersensitivity reactions, including anaphylaxis, angioedema, dyspnea, rash, and urticaria have been reported; reactions may occur days after administration and may be prolonged. Discontinue use and initiate appropriate therapy if hypersensitivity reactions occur.
• Cardiovascular disease: Patients with ECG abnormalities compatible with an acute cardiovascular event and patients with a recent history (within 6 months) of stroke, myocardial infarction, unstable angina, percutaneous coronary intervention, coronary artery bypass grafting, deep vein thrombosis, or pulmonary embolism were excluded from clinical trials; use with caution in these patients.
• Peripheral vascular disease: Patients with history of stroke, intracranial or carotid aneurysm, intracranial hemorrhage, vasospastic angina or Raynaud disease, or clinical evidence of peripheral vascular disease were excluded from cluster headache clinical trials; use with caution in these patients.
Dosage form specific issues:
• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.
• Appropriate use: Patients on any other migraine or cluster headache preventive treatment and patients with medication overuse headache were excluded from clinical trials; use with caution in these patients.
• Immunogenicity: Anti-galcanezumab antibodies and neutralizing antibodies may develop.
Number of monthly migraine days or weekly cluster headache attack frequency
Consider the long half-life prior to use in females who may become pregnant until information related to pregnancy is available (Tepper 2018).
Adverse events were not observed in animal reproduction studies.
Galcanezumab is a humanized monoclonal antibody (IgG4). Potential placental transfer of human IgG is dependent upon the IgG subclass and gestational age, generally increasing as pregnancy progresses. The lowest exposure would be expected during the period of organogenesis (Palmeira 2012; Pentsuk 2009).
Consider the long half-life prior to use in females who are pregnant until information related to pregnancy is available (Tepper 2018).
What is this drug used for?
• It is used to prevent migraine headaches.
• It is used to treat cluster headaches.
WARNING/CAUTION: Even though it may be rare, some people may have very bad and sometimes deadly side effects when taking a drug. Tell your doctor or get medical help right away if you have any of the following signs or symptoms that may be related to a very bad side effect:
• Injection site irritation
• Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing, swallowing, or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.
Note: This is not a comprehensive list of all side effects. Talk to your doctor if you have questions.
Consumer Information Use and Disclaimer: This information should not be used to decide whether or not to take this medicine or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a limited summary of general information about the medicine's uses from the patient education leaflet and is not intended to be comprehensive. This limited summary does NOT include all information available about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this medicine. This information is not intended to provide medical advice, diagnosis or treatment and does not replace information you receive from the healthcare provider. For a more detailed summary of information about the risks and benefits of using this medicine, please speak with your healthcare provider and review the entire patient education leaflet.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
- Emgality vs Aimovig - how do they compare?
- Does Emgality cause weight gain?
- Ubrelvy vs Emgality: How do they compare for migraines?
- What are the new drugs for the treatment and prevention of migraine?
- How long does it take for Emgality to work?
- Do Emgality injections hurt?
- How does Emgality work?
- What is the cost of the migraine drug Ajovy?
- What type of drug is Ajovy?
- What type of drug is Emgality?
More about galcanezumab
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Support Group
- En Español
- 221 Reviews
- Drug class: CGRP inhibitors
Other brands: Emgality